Oncology
Tumors arise in a complex and dynamic microenvironment that influences growth, invasion, and metastasis.
Based on this understanding, we focused on the major signaling pathways that affect tumor cells, immune cells, and the stroma that comprise the tumor microenvironment.
Our approaches
- Exploring novel drug targets based on the understanding of the tumor microenvironment
- Choosing the right therapeutic modality
Ongoing Programs
| Program | Target | Stage | Modality |
| Immuno-oncology | |||
| DA-4505 | AHR | Phase 1 | SM |
| Oncology | |||
| DA-4531 | PARP7 | Lead op. | SM |
| DA-4701 | EGFR | Lead op. | TPD |
| TME modulation | |||
| DA-3101 | aFAP x IL-12v | Preclinical | mAb |
| Antibody-based therapeutics | |||
| Discovery 1 | CD171 | Hit op. | ADC |
| Discovery 2 | Claudin 18.2 x HER2 | Hit op. | bsADC |
| Discovery 3 | HER2 x AXL | Hit op. | bsADC |
| Discovery 4 | Nectin4 x PD-L1 | Hit op. | bsADC |
